Skip to main content

Drug Interactions between mifepristone and selexipag

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

miFEPRIStone selexipag

Applies to: mifepristone and selexipag

MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase exposure to the active metabolite of selexipag. According to the prescribing information, selexipag is hydrolyzed to its active metabolite in the liver and intestine by carboxylesterases, and the active metabolite subsequently undergoes oxidative metabolism catalyzed primarily by CYP450 2C8 and to a lesser extent by CYP450 3A4. Coadministration of selexipag with the moderate to potent CYP450 2C8 inhibitor clopidogrel, given at 300 mg loading dose or 75 mg once daily maintenance dose, had no relevant effect on exposure to selexipag but increased exposure to the active metabolite by approximately 2.2- and 2.7-fold following the loading and maintenance doses, respectively. The interaction has not been studied with other, less potent CYP450 2C8 inhibitors.

MANAGEMENT: Caution is advised when selexipag is prescribed with CYP450 2C8 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring of selexipag may be appropriate whenever a CYP450 2C8 inhibitor is added to or withdrawn from therapy. Patients should be monitored for potentially increased side effects such as diarrhea, nausea, vomiting, flushing, anemia, and decreased appetite.

References (4)
  1. (2001) "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."
  4. (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc

Drug and food interactions

Moderate

miFEPRIStone food

Applies to: mifepristone

ADJUST DOSING INTERVAL: Food may significantly increase the plasma concentrations of mifepristone.

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of mifepristone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, it should be taken with food to achieve consistent plasma drug levels. Patients should be advised to avoid consuming grapefruit or grapefruit juice during treatment with mifepristone, as it may cause increased adverse effects such as headache, dizziness, fatigue, nausea, vomiting, cramping, diarrhea, hypokalemia, adrenal insufficiency, vaginal bleeding, arthralgia, peripheral edema, and hypertension. Because mifepristone is eliminated slowly from the body, the interaction with grapefruit juice may be observed for a prolonged period.

References (2)
  1. (2001) "Product Information. Mifeprex (mifepristone)." Danco Laboratories
  2. (2012) "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated
Minor

selexipag food

Applies to: selexipag

Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.

References (1)
  1. (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.